Study S001653

A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT04881760
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 338
Start: 2021-05-20
Primary completion: 2022-05-16
Lead sponsor: Eli Lilly and Company
Conditions: Obesity; Overweight
Interventions: DRUG:LY3437943; DRUG:Placebo
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:J1I-MC-GZBF

Registered primary outcomes

Mean Percent Change From Baseline in Body Weight [Baseline, Week 24]

Linked records (6)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0008617	Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. Ruotolo G, Diabetes, obesity & metabolism	2026	Randomized trial	PMID 42608321 DOI	cites ClinicalTrials.gov:NCT04881760; registry reference DERIVED:42608321
R0018230	Development of the Weight and Emotions Scale (WES). Kanu C, Obesity science & practice	2026	Other trial	PMID 41589220 DOI	cites ClinicalTrials.gov:NCT04881760
R0020165	Development and Content Evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity. Kanu C, Advances in therapy	2026	Other trial	PMID 41201783 DOI	cites ClinicalTrials.gov:NCT04881760; registry reference DERIVED:41201783
R0013072	Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial. Goetz IA, Obesity pillars	2025	Randomized trial	PMID 41216380 DOI	cites ClinicalTrials.gov:NCT04881760
R0016993	Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Sanyal AJ, Nature medicine	2024	Randomized trial	PMID 38858523 DOI	cites ClinicalTrials.gov:NCT04881760; registry reference DERIVED:38858523
R0015688	Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. Jastreboff AM, The New England journal of medicine	2023	Randomized trial	PMID 37366315 DOI	cites ClinicalTrials.gov:NCT04881760; registry reference DERIVED:37366315